Dr. Brown leads Kapoose Creek Bio and is a Distinguished University Professor at McMaster University in the Department of Biochemistry and Biomedical Sciences. He is known for a large body of top-flight research in antibiotic discovery and for innovating in diverse areas of drug discovery, using tools of chemical and systems biology to probe the complexity that underlies disease. Dr. Brown is a Fellow of the Royal Society of Canada and has received a number of other awards including the Canadian Society of Microbiologists Murray Award for career achievement.

Mr. Jackson is a Chartered Accountant and Corporate Director with over 25 years of M&A and operations experience with both public and private companies. He has a Bachelor of Commerce degree from the University of Saskatchewan, and is a designated member of the Chartered Professional Accountants of British Columbia and the Institute of Corporate Directors of Canada.

Dr. Stewart has an extraordinary background at the nexus of science and business. He is a McMaster alumni with both a PhD (Biochemistry) and MBA. Dr. Stewart has co-founded and led several innovative technology firms and served as an advisor to many Canadian companies, entrepreneurs and investors in the biotechnology and technology sectors.

Dr. Czarny holds a PhD from McMaster University Faculty of Health Sciences and an MBA from York University’s Schulich School of Business. Dr. Czarny has a strong background in leadership and project management at SickKids Research Institute in Toronto, where he has directed the organizations Precision Child Health initiative, a major effort of diverse stakeholders, including star researchers, industrial partners, and philanthropists.

Dr. Landon holds a PhD in Bioinformatics from Boston University and has charted a career path in business development in the biotechnology sector. She has a strong background and network of partners and investors in the US life sciences sector. She Most recently, she was Chief Strategy Officer for Cyclica, a Canadian AI drug discovery company that was acquired in a high-profile transaction by publicly traded Recursion Pharmaceuticals.

Mr. Walle holds a Bachelor of Science degree from the University of Victoria in Biochemistry. He has deep expertise in cultivating and extracting compounds from medicinal mushrooms in academic, clinical and pharmacological settings. He has led pioneering work with Victoria based non-profits facilitating and exploring the role of psilocybin in treating addiction. He has a background combining more than a decade of laboratory work in therapeutics and biochemistry, human capital management, business, media and applied mycology.

Ms. De Gouw studied Marine Biology at the University of Victoria and has worked in fungal cultivation for nearly a decade, where she has played a critical role in spawn development, bulk substrate preparation, harvest, and pest management. These skills are complimented by a strong background working in research laboratories, staffing, SOP development, client care and inventory management.

Mr. Feldman is a successful music business executive, serial entrepreneur, and investor. With nearly 50 years of experience in the music, media, and entertainment sectors, Sam has become a Canadian icon, honing his ability to identify, bring together, and manage some of the world’s most influential talent. He is a full partner in A&F Music Ltd and its group of companies, which include Macklam Feldman Management, Bruce Allen Talent, Watchdog Management, The Characters Talent Agency, and INF Influencer Agency. Mr. Feldman is also a Canadian Music Industry Hall of Fame and BC Entertainment Hall of Fame Inductee.

Mr. Petrelli is a biotechnology/pharmaceutical industry leader with a proven track record of success built over 23 years of experience at companies like GlaxoSmithKline, AstraZeneca, Biogen and most recently, Jazz Pharmaceuticals, which under his leadership has been recognized as a Great Place to Work in Canada. Paul's experience includes extensive product launch expertise, lifecycle management and breadth of understanding in sales, marketing, market access, medicine, government relations and regulatory affairs.

Dr. Balboni is a partner, senior advisor and member of the Board of Directors of Bloom Burton & Co., a leading Canadian advisory firm that specializes in accelerating the path to monetization for high potential life sciences and biotech companies. He recently completed a period of active duty in the U.S. Army as the Deputy Director, Office of Regulated Activities (ORA), an 80-person team that provides clinical and regulatory oversight and advisement for more than 100 FDA clinical trials and all associated regulatory filings and approval processes.

Ms. Biln has over 30 years of experience across a range of commercial roles at Pfizer Pharmaceuticals, Amgen and Abbott Laboratories; has served as a director on the board of several biotechnology organizations; and has been recognized as one of Canada's Most Powerful Women and a leading figure in the Canadian biotech sector.

Dr. Max Cynader CM OBC PH.D FRSC FCAHS is the Founding Director of the Brain Research Centre, and the Djavad Mowafaghian Centre for Brain Health at UBC. Max is one of Canada’s leading neuroscientists and his research career includes studies of neuroplasticity, visual and auditory processing mechanisms, and neurodegenerative disorders. He has received many honours and awards, including the Order of Canada, the Order of British Columbia , Fellow of The Royal Society of Canada, Fellow of The Canadian Academy for Health Sciences, and induction into the Canadian Medical Hall of Fame. He was a semi-finalist in the Canadian Astronaut Programme and has served as President of the Canadian Association for Neuroscience. Max is also a serial entrepreneur, and has founded or cofounded four startups based on advances in Neuroscience research.

Dr. Cowen is Vice-President, Research and Innovation, and Strategic Initiatives at the University of Toronto, Professor in the Department of Molecular Genetics, co-Director of the CIFAR Fungal Kingdom: Threats & Opportunities program, and co-Founder and Chief Scientific Officer of Bright Angel Therapeutics, a company focused on development of novel antifungals. She has received a Burroughs Wellcome Fund Career Award, Grand Challenges Canada Star in Global Health Award, E.W.R. Steacie Award, and Canada Research Chair in Microbial Genomics & Infectious Disease. She is an elected Fellow of the American Academy of Microbiology and the American Association for the Advancement of Science.

André Brown is a Reader in Behavioural Phenomics at Imperial College London and a Programme Leader at the MRC London Institute of Medical Sciences. He has made conceptual and technical advances in whole-animal tracking, behavioural profiling, and machine learning applied to phenotypic screens. His lab has developed a platform for tracking the response of nematode worms to drugs at unprecedented throughput and applied it to model rare genetic diseases, predict the mode of action of drugs, and detect the effects of microbes on the nervous system.André has consulted with agchem and biotech companies including Syngenta and Perlara on the use of worm screens in pesticide discovery and drug repurposing.

Dr. Wright is the M.G. DeGroote Chair in Infection and Anti-Infective Research and Professor in the Department of Biochemistry and Biomedical Science at McMaster University. He was the founding director of the DeGroote Institute for Infectious Disease Research (2007-2022), the David Braley Centre for Antibiotic Discovery (2018-2022), and McMaster’s Global Nexus School for Pandemic Prevention and Response (2020-2023). Gerry was elected as a Fellow of the Royal Society of Canada (2012) and the American Academy of Microbiology (2013). His research interests are in the mechanisms of antibiotic resistance and the discovery of microbial natural products using synthetic biology methods.